| 1.42 -0.03 (-2.07%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.89 | 1-year : | 2.21 |
| Resists | First : | 1.62 | Second : | 1.89 |
| Pivot price | 1.45  |
|||
| Supports | First : | 1.37 |
Second : | 1.23 |
| MAs | MA(5) : | 1.43 | MA(20) : | 1.41 |
| MA(100) : | 1.44  |
MA(250) : | 1.38 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 42.1 |
D(3) : | 45.6 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 2 | Low : | 1.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GERN ] has closed above bottom band by 43.0%. Bollinger Bands are 45.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.46 - 1.47 | 1.47 - 1.47 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.43 - 1.44 | 1.44 - 1.45 |
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Thu, 23 Jul 2026
Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 22 Jul 2026
Five New Geron Hires Receive Options at $1.44 Per Share - Stock Titan
Wed, 22 Jul 2026
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wed, 22 Jul 2026
Geron Corporation (GERN) Q1 2025 Earnings Report - Results, Call & Slides - TipRanks
Wed, 22 Jul 2026
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 - Moomoo
Tue, 14 Jul 2026
Geron's New Business Chief Gets Option on 1.7M Shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 642 (M) |
| Shares Float | 536 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 79.6 (%) |
| Shares Short | 80,220 (K) |
| Shares Short P.Month | 71,770 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | -34.4 % |
| Operating Margin | -0.5 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -27.1 % |
| Qtrly Rev. Growth | 30.8 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -126 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -13.1 |
| PEG Ratio | 0 |
| Price to Book value | 4 |
| Price to Sales | 4.71 |
| Price to Cash Flow | -7.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|